增长6.1%，赛多利斯2025上半年业绩报告

Core Viewpoint - Sartorius reported a sales revenue of €1.767 billion for the first half of 2025, marking a year-on-year growth of 6.1%, primarily driven by the bioprocess solutions segment and laboratory products and services [3][4]. Group 1: Financial Performance - The company achieved a sales revenue growth of 6.1% in the first half of 2025 [4]. - The bioprocess solutions segment generated €1.435 billion, with a year-on-year growth of 8.8% [4]. - The laboratory products and services segment reported a revenue of €332 million, showing a decline of 4.0% when adjusted for fixed exchange rates [5]. Group 2: Business Segments - The bioprocess solutions segment is expected to grow approximately 7% for the full year 2025, supported by a rich product portfolio that enhances drug production efficiency [6]. - The laboratory products and services segment is projected to grow about 1% for the full year 2025, with new products aimed at accelerating drug development [6]. Group 3: Management Outlook - The management confirmed the full-year guidance for 2025, anticipating an organic sales revenue growth of around 6% [6]. - The CEO expressed satisfaction with the first half performance and emphasized the importance of high-margin consumables in the pharmaceutical sector [4].